Cost-Benefit Analysis of GLP-1 Coverage for Obesity in New Hampshire
Executive Summary
Glucagon-like peptide-1 receptor agonists (GLP-1s) are a group of medications effective at treating obesity, type-2 diabetes, and other conditions. GLP-1s are a desirable treatment option for many Americans, but they are costly. Spending from Medicaid and private payers on GLP-1s is rising at an unprecedented rate. Federal stipulations require Medicaid to cover GLP-1s for obesity-related comorbidities, such as diabetes, but not exclusively for obesity. New Hampshire Senate Bill 455 (SB455) seeks to expand Medicaid coverage of GLP-1s to individuals with a Body Mass Index (BMI) of 30 or higher even if they do not have an associated comorbidity. What impact will SB455’s enhanced GLP-1 coverage have on New Hampshire’s health and finances? Using a combination of qualitative and quantitative methods, this report synthesizes:
1) The federal and state policy landscape for GLP-1 coverage
2) Health information about obesity and GLP-1s
3) The long-term financial impact of SB455 at the state-level
4) Recommendations to improve quality of care and control costs